(MT Newswires) -- Novo Nordisk (NVO) Chief Executive Officer Lars Fruergaard Jorgensen discusses the possibility of its Ozempic drug's inclusion on the Biden administration's list of prescription drugs that will be subject to price negotiations with Medicare, US demand for its obesity medicine Wegovy, and acquisition strategy on Bloomberg Television.

Bloomberg videos